eligibility_summary
Adults 18–85 with advanced CRC (MMR‑proficient), gastric/GEA, or ovarian cancer after 1–3 prior lines (Phase 1b GEA post‑ICI). Need ≥1 injectable lesion 1–6.5 cm (LN 1.5–6.5), none >6.5, hepatic burden <1/3, ECOG 0–1, adequate organs. Exclude curative liver option/need systemic tx, ascites, uncontrolled illness, steroids, bleeding risk, recent ICI/tx/vaccines, CNS mets, HIV/HBV/HCV, infection, other cancer <3 y, ILD, transplant, autoimmune disease, immunodeficiency, SBO, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Interventions and mechanisms: IVX037 is a bioselected oncolytic RNA virus delivered intratumorally. It selectively infects/replicates in tumor cells, inducing oncolysis and immunogenic cell death, releasing tumor antigens and danger signals that activate innate sensing (type I interferon) and drive dendritic cell activation/cross-presentation and cytotoxic T-cell priming—aiming to inflame typically “cold” MSS tumors. In Part 1b, IVX037 is combined with sintilimab, an anti-PD-1 IgG4 monoclonal antibody checkpoint inhibitor that blocks PD-1 to prevent T-cell exhaustion and enhance effector function. Targets/pathways: tumor cells (viral oncolysis), innate immune pathways and antigen-presenting cells, CD8+ T cells, PD-1/PD-L1 checkpoint in the tumor microenvironment.